TriGemX Bio to go public in $600M TCGX merger

What happened: TriGemX Bio, a biotechnology company developing migraine treatments, agreed to go public through a merger with TCGX Acquisition Corp. (TCGX). Key numbers: $600M merger value; $246M in expected gross proceeds, including a $160M private placement and $86M in trust. Why it matters: The transaction would take TriGemX Bio public via a merger with the TCGX acquisition vehicle, with proceeds split between a private placement and trust funds.

TriGemX Bio, a biotechnology company developing migraine treatments, agreed to go public through a merger with TCGX Acquisition Corp. (TCGX).

The transaction would take TriGemX Bio public via a merger with the TCGX acquisition vehicle, with proceeds split between a private placement and trust funds.